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5 fluorouracil (5FU) has been a first-choice chemotherapy drug for several cancer
types (e.g., colon, breast, head, and neck); however, its efficacy is diminished by
patient acquired resistance and pervasive side effects. Leukopenia is a hallmark of 5FU;
however, the impact of 5FU-induced leukopenia on healthy tissue is only becoming
unearthed. Recently, skeletal muscle has been shown to be impacted by 5FU in
clinical and preclinical settings and weakness and fatigue remain among the most
consistent complaints in cancer patients undergoing chemotherapy. Monocytes, or
more specifically macrophages, are the predominate immune cell in skeletal muscle
which regulate turnover and homeostasis through removal of damaged or old materials
as well as coordinate skeletal muscle repair and remodeling. Whether 5FU-induced
leukopenia extends beyond circulation to impact resident and infiltrating skeletal muscle
immune cells has not been examined. The purpose of the study was to examine
the acute effects of 5FU on resident and infiltrating skeletal muscle monocytes and
inflammatory mediators. Male C57BL/6 mice were given a physiologically translatable
dose (35 mg/kg) of 5FU, or PBS, i.p. once daily for 5 days to recapitulate 1 dosing
cycle. Our results demonstrate that 5FU reduced circulating leukocytes, erythrocytes,
and thrombocytes while inducing significant body weight loss (>5%). Flow cytometry
analysis of the skeletal muscle indicated a reduction in total CD45+ immune cells with
a corresponding decrease in total CD45+CD11b+ monocytes. There was a strong
relationship between circulating leukocytes and skeletal muscle CD45+ immune cells.
Skeletal muscle Ly6cHigh activated monocytes and M1-like macrophages were reduced
with 5FU treatment while total M2-like CD206+CD11c- macrophages were unchanged.
Interestingly, 5FU reduced bone marrow CD45+ immune cells and CD45+CD11b+
monocytes. Our results demonstrate that 5FU induced body weight loss and decreased
skeletal muscle CD45+ immune cells in association with a reduction in infiltrating
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Ly6cHigh monocytes. Interestingly, the loss of skeletal muscle immune cells occurred
with bone marrow cell cycle arrest. Together our results highlight that skeletal muscle is
sensitive to 5FU’s off-target effects which disrupts both circulating and skeletal muscle
immune cells.
Keywords: chemotherapy, monocytes, macrophages, skeletal muscle, bone marrow
BACKGROUND
The increase in 5-year survival rate among cancer patients has
increased focus on quality of life to improve patient outcomes
(Curt et al., 2000). In addition to cancer-associated wasting
and functional decrements, the most commonly prescribed
chemotherapies have pervasive off-target effects that have been
reported to impact quality of life (Iacovelli et al., 2014; Lee
et al., 2014; Polk et al., 2014; Ribeiro et al., 2016). 5 fluorouracil
(5FU) has been the first-choice chemotherapy drug for several
cancer types for many years (van Kuilenburg and Maring, 2013;
Giuliani and Bonetti, 2016; Lee et al., 2016; McQuade et al.,
2017); however, 5FU negatively impacts the gastro-intestinal
system (Lee et al., 2014; Ribeiro et al., 2016; Sougiannis et al.,
2019), cardiovascular system (Polk et al., 2014; Phillips et al.,
2018), hematopoietic system (Kvinnsland, 1999; Shitara et al.,
2009; Han et al., 2012), and has recently been shown to directly
disrupt skeletal muscle (Barreto et al., 2016b; Botsen et al.,
2018; Williams et al., 2018). Disruptions to skeletal muscle
homeostasis contributes to functional dependency and poor
treatment outcomes and ultimately leads to increased healthcare
costs and decreased survival (Barreto et al., 2016b). Currently,
there are no Food and Drug Administration approved therapies
for chemotherapy-induced cachexia despite the importance of
skeletal muscle and lean mass in sustaining 5FU’s therapeutic
efficacy and patient quality of life (Sandini et al., 2018; Williams
et al., 2018). This is not entirely surprising given that very little
is known about the mechanisms responsible for 5FU-induced
skeletal muscle dysfunction. Thus, identifying the factors driving
chemotherapy-induced skeletal muscle dysfunction is critical to
developing effective interventional therapies.
Despite 5FU-induced leukopenia remaining a hallmark of
treatment (Shitara et al., 2011; Sougiannis et al., 2019),
investigations into the impact of 5FU on skeletal muscle have
largely focused on metabolism (Barreto et al., 2016a,b). Notably,
there is a dearth of evidence on the influence of 5FU on
skeletal muscle inflammation – a process that is known to
play a role in skeletal muscle homeostasis (Costamagna et al.,
2015). Indeed, inflammation can play a paradoxical role in
skeletal muscle homeostasis. During normal conditions pro-
inflammatory cytokines are required to balance anabolism
Abbreviations: 5FU, 5 fluorouracil; BSA, bovine serum albumin; CD, cluster
of differentiation; DMEM, Dulbecco’s Modified Eagle Medium; EDTA,
Ethylenediaminetetraacetic acid; FBS, fetal bovine serum; FSC, forward scatter;
HCT, Hematocrit; HGB, Hemoglobin; IFN, interferon; IL, Interleukin; Ly6c,
lymphocyte antigen 6c; LYM, lymphocyte; MCP, monocyte chemoattractant
protein; MON, monocyte; NEU, neutrophil; PBS, phosphate buffered saline; PLT,
platelets; RBC, red blood cell; SEM, standard error of the mean; SSC, side scatter;
STAT, signal transducer and activator of transcription; TAM, tumor associated
macrophage; TGF, transforming growth factor; TNF, tumor necrosis factor; WBC,
white blood cell.
and catabolism and to maintain normal myogenic processes.
However, during disease conditions, pro-inflammatory cytokines
can induce catabolic pathways that impair skeletal muscle
integrity and function (Sharma and Dabur, 2020). To date, our
understanding of 5FU-induced inflammatory changes is limited
to circulating inflammatory cytokines and intrinsic inflammatory
signaling. Additionally, the available studies highlight equivocal
results showing increased circulating interleukin (IL) 6, tumor
necrosis factor α (TNFα), monocyte chemoattractant protein
(MCP) 1 (Wang et al., 2012; Mahoney et al., 2013, 2014), with
reduced or unchanged skeletal muscle inflammatory protein
expression (Barreto et al., 2016a,b). Given the importance of
skeletal muscle to quality of life in chemotherapy patients along
with the well-documented effects of inflammation on skeletal
muscle homeostasis, it is important to assess inflammatory
mediators as a potential target for chemotherapy-induced skeletal
muscle dysfunction (Kvinnsland, 1999; Yamanaka et al., 2007;
Shitara et al., 2009; Baechler et al., 2010; Han et al., 2012; Abraham
et al., 2015).
The lack of evidence on 5FU associated perturbations in
skeletal muscle inflammation is consistent with a scarcity of
literature on 5FU effects on skeletal muscle immune cells.
Monocytes, or more specifically macrophages, are the most
abundant skeletal muscle immune cell which function to
regulate tissue turnover and homeostasis (Tidball, 2017).
Targeting macrophages is emerging as a potential key regulator
of chemotherapeutic efficacy given the importance of tumor
associated macrophages (TAM) in tumorigenesis, tumor
vascularization, and local immunosuppression (Mantovani and
Allavena, 2015); however, the effects of 5FU on skeletal muscle
macrophages is largely unexplored. Resident skeletal muscle
monocytes are classically characterized as CD11b+Ly6cLow
monocytes and F4/80+CD11c-CD206- (quiescent – M0)
macrophages (Krippendorf and Riley, 1993; Tidball, 2017).
Circulating CD11b+Ly6CHigh activated monocytes, recruited
by MCP-1, extravasate the muscle (Deshmane et al., 2009; Liao
et al., 2018) and either remain CD11b+Ly6CHigh or differentiate
to F4/80+CD11c+CD206- pro-inflammatory, pro-phagocytic
(M1-like) macrophages which secrete pro-inflammatory
cytokines, IL-6, IL-1β, TNFα, and interferon (IFN) γ (Frenette
et al., 2003; Guilliams et al., 2014). These M1-like macrophages
will then down regulate CD11c expression and increase CD206+
to reflect a more anti-inflammatory, pro-fibrotic (M2-like)
macrophage which secrete anti-inflammatory cytokine IL-10
and pro-fibrotic cytokine transforming growth factor (TGF)
β (Gordon and Taylor, 2005; Arnold et al., 2007; Reidy et al.,
2019). Proper balance of these immune cell phenotypes and
maintenance of immune cell number are vital for skeletal muscle
homeostasis. Thus, determination of 5FU’s effects on skeletal
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FIGURE 1 | Animal characteristics. 5-fluorouracil (5FU) was solubilized in phosphate buffered saline at 3.5 mg/mL and administered to the mice at 35 mg/kg via
intraperitoneal injection once daily for 5 days. (A) Relative body weight change shown as the % change from day 0 throughout the duration of the study. (B) Daily
food intake in grams throughout the duration of the study. Dotted line illustrates the average daily food intake in grams (g) per day over the course of the 5 days of
treatment. (C) Select hindlimb muscle weights given in milligrams (mg) after 5 days of 5FU. (D) Select organ weights in mg after 5 days of 5FU. (E) Circulating
leukocytes given as # of cells × 109/L after 5 days of 5FU. (F) Circulating erythrocytes and thrombocytes given as # of cells × 109/L after 5 days of 5FU. Sol, soleus;
Plan, plantaris; Gas, gastrocnemius; TA, tibialis anterior; EDL, extensor digitorum longus; Quad, quadriceps; Lym, lymphocytes; Mon, monocytes; Neu, neutrophils;
RBC, red blood cells; HBG, hemoglobin; HCT, hematocrit; PLT, platelets. Significance was set at p < 0.05. *Significantly different from Control using a student’s
t-test. #Significantly different from Day 0 using a repeated measures Two-way ANOVA.
muscle immune populations is essential for the development of
effective treatment strategies.
Skeletal muscle immune cell depletion has been demonstrated
to delay recovery and disrupt extracellular matrix remodeling
leading to fibrosis, weakness, and metabolic homeostatic
imbalance (Farini et al., 2007; Liu et al., 2017). While results
pertaining to intrinsic skeletal muscle inflammatory signaling
with several chemotherapies are equivocal, leukopenia has been
well established (Kvinnsland, 1999; Yamanaka et al., 2007; Shitara
et al., 2009; Baechler et al., 2010; Han et al., 2012; Abraham
et al., 2015). The overall purpose of the current study was to
investigate the acute effects of 5FU on resident and infiltrating
skeletal muscle monocytes and inflammatory mediators. We
hypothesized that an acute dosing regimen of 5FU would deplete
circulating and skeletal muscle monocytes and reduce associated
inflammatory cytokines consistent with systemic leukopenia. Our
results demonstrate that 1 cycle of 5FU was sufficient to induce
significant body weight loss and leukopenia associated with a loss
of total skeletal muscle immune cells and a reduction in select
inflammatory mediators. Additionally, we show 5FU induced
bone marrow cell cycle arrest which is likely to contribute to the
observed loss of infiltrating skeletal muscle monocytes.
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FIGURE 2 | The effects of 5FU on skeletal muscle immune cells. (A) Cells were gated for non-debris (SSC-A × FSC-A), (B) FSC singlets (FSC-W × FSC-H), (C) and
SSC singlets (SSC-W × SSC-H; A-right). (D) Non-debris singlet cells were then gated for total immune cells with CD45+. (E) CD45+ cells were quantified and
shown in the bar graph as the relative % of non-debris singlets. (F) CD45+ cells were gated for monocytes with CD11b+. (G) CD45+CD11b+ cells were quantified
and shown in the bar graph as the relative % of CD45+ cells. (H) CD45+CD11b+ were then gated for macrophages with F4/80. (I) F4/80+ cells were quantified and
shown in the bar graph as the relative % of CD45+CD11b+ cells. Significance was set at p < 0.05. *Significantly different from Control using a student’s t-test.
MATERIALS AND METHODS
Animals
Eighteen male C57BL/6 mice were purchased from Jackson
Laboratories at 4 weeks of age and housed in the Department
of Laboratory Animal Resources at the University of South
Carolina. Mice were either group housed (n = 12) or singly
housed to measure food intake (n = 6) and kept on a 12:12-
h light-dark cycle. Animals were placed on a purified AIN-
76A (Bio-Serv, Frenchtown, NJ, United States; catalog#:F1515)
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TABLE 1 | Skeletal muscle immune cell population.
Total Non-debris FSC Singlet SSC Singlet CD45+ CD45+ CD11b+ CD45+ CD11b+ F4/80+
Control Mean 500000 357171 300554 293303 8313 6986 2509
SEM 0 (9278) (12211) (12898) (1112) (1092) (531)
5FU Mean 500000 329763 265158 257197 4412* 3701* 1084*
SEM 0 (12996) (15057) (15433) (397) (384) (182)
p-value 0.207 0.180 0.171 0.005 0.009 0.013
Values are means ± SEM. Total number of cells counted. Absolute number of non-debris cells from the total number of cells. Absolute number of forward scatter (FSC)
single cells from the non-debris cells. Absolute number of side scatter (SSC) single cells from the FSC single cells. Absolute number of CD45+ cells from the SSC single
cells. Absolute number of CD45+CD11b+ cells from SSC single cells. Absolute number of CD45+CD11b+F4/80+ cells from SSC single cells. Significance was set at
p < 0.05. *Significantly different from Control using a student’s t-test.
diet for 5 weeks prior to any experimental procedures. Body
weights were measured weekly, and animals were monitored for
signs of distress. Animals were given food and water ad libitum
throughout the duration of the study. All animals were fasted
5 h prior to tissue collection. Mice were anesthetized with
isoflurane and hindlimb muscles, select organs, and both femurs
were carefully dissected, weighed, and either snap frozen in
liquid nitrogen or placed in the appropriate buffers for flow
cytometry analysis. All animal experiments were approved by
the University of South Carolina’s Institutional Animal Care
and Use Committee.
Experimental Design
At 14 weeks of age mice were randomized into two groups,
Control (n = 9) and 5FU (n = 9). 5FU was solubilized in PBS
at 3.5 mg/mL and administered to the mice at 35 mg/kg i.p.
once daily for 5 days. This dosing regimen has been previously
shown to be comparable to clinical doses and recapitulates 1 cycle
of chemotherapy (Phillips et al., 2018; Sougiannis et al., 2019).
Control mice received a PBS injection. Tissue was collected and
the animals were euthanized 24 h following the final injection.
Blood Analysis
Blood was collected at euthanasia via the inferior vena cava,
placed in an EDTA coated vacutainer (VWR, Suwanee, GA,
United States; catalog#:454428) and stored briefly on ice until
analysis. A complete blood count was performed using the
VetScan HMT (Abaxis, Union City, CA, United States) for
determination of white blood cells (WBCs), lymphocytes (LYM),
monocytes (MON), neutrophils (NEU), red blood cells (RBCs),
Hemoglobin (HGB), Hematocrit (HCT), and platelets (PLT).
Flow Cytometry
Both quadriceps were excised, minced in Dulbecco’s Modified
Eagle Medium (DMEM), and cells were extracted using the
skeletal muscle dissociation kit (Miltenyi Biotec, Auburn, CA,
United States; cat#; 130-098-305) following the manufacture’s
instruction. Both quadriceps were pooled to obtain a sufficient
number of cells for each analysis without pooling animals
(n = 9/group). Skeletal muscle cells were suspended in flow
buffer (0.5% BSA, 2 mM EDTA, PBS). Following hindlimb
muscle excision, both femurs (n = 5/group) were cleaned
and placed in ice cold PBS. The epiphysis of the femurs
was removed, and the bone marrow was flushed with PBS
using a 26G syringe. Cells were then passed through a 70-
µm filter and suspended in flow buffer (2% FBS-PBS). Red
blood cell lysis was performed with 20 second hypotonic
solution (0.2% NaCl) treatment followed by hypertonic (1.6%
NaCl) cessation. This method has been shown to reduce
disturbances to cell surface markers compared to alternative
RBC lysis buffers (Swamydas and Lionakis, 2013). Both skeletal
muscle and bone marrow cells were blocked with Fc-block
against CD16 and CD32 in their respective flow buffers.
Cells were then incubated with fluorescently labeled antibodies
against CD45 (PE/CY7), CD11b (APC), Ly6c (PerCP/Cy5.5),
F4/80 (FITC), CD11c (APC/Cy7), and CD206 (PE). Cells were
measured using a FACS Aria II and analyzed using FlowJo
V10.6.2 (BD Biosciences, Ashland, OR, United States). Prior to
cellular analysis, all colors were compensated using Invitrogen
UltraComp eBeadsTM Compensation Beads (Life technologies,
Carlsbad CA, United States). A total of 5 × 105 skeletal muscle
cells and 3× 105 bone marrow cells were analyzed.
RNA Isolation and RT-PCR
RNA isolation, cDNA synthesis, and real-time PCR were
performed as previously described (Sougiannis et al., 2019)
using reagents from Applied Biosystems (Foster City,
CA, United States). Briefly, RNA was extracted from the
gastrocnemius using the TRIzol/isopropanol/chloroform
procedure (Life Technologies, GIBCO-BRL, Carlsbad, CA,
United States). RNA sample quality and quantities were verified
using a Nanodrop One Microvolume UV-Vis Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, United States)
and determined to be of good quality based on A260/A280
values (>1.8) prior to cDNA synthesis using High capacity
Reverse Transcriptase kit (Applied Biosystems, Foster City, CA,
United States). Probes for MCP-1, IL-6, IL-1β, IL-10, TNF-α,
IFNγ, CD11c, CD206, F4/80, and CD68 as well as housekeeping
genes Hmbs, B2M, TBP, H2afv, and 18s were purchased
from Applied Biosystems (Foster City, CA, United States).
Quantitative RT-PCR analysis was carried out as per the
manufacturer’s instructions (Applied Biosystems, Foster City,
CA, United States) using Taq-Man Gene Expression Assays
on a Qiagen Rotor-Gene Q. Data were normalized to vehicle
treated controls and compared to five reference targets (Hmbs,
B2M, TBP, H2afv, and 18s), which were evaluated for expression
stability using GeNorm (St-Pierre et al., 2017).
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FIGURE 3 | The effects of 5FU on skeletal muscle macrophage gene expression. (A) Relative gene expression of total macrophage genes, CD68 and Emr1 (F4/80),
M1-like macrophage gene, Itgax (CD11c), and M2-like macrophage gene, Mrc1 (CD206). (B) Relative gene expression of pro-inflammatory genes, Interleukin (IL) 6,
IL-1β, Interferon (IFN) γ, Tumor necrosis factor (TNF) α, and monocyte chemoattractant protein (MCP) 1. (C) Relative gene expression of anti-inflammatory genes
IL-10 and transforming growth factor (TGF) β. Significance was set at p < 0.05. *Significantly different from Control using a student’s t-test.
Statistics
Values are presented as means ± standard error of the
mean (SEM). Student t-tests were performed to determine
the differences between 5FU and Control for all endpoint
measurements. A repeated measures two-way ANOVA was used
to determine a difference in body weight change and food
intake (treatment × time). Post hoc analysis were performed
with student Newman-Keuls methods. A Bartlett’s test was
used to determine significantly different standard deviations.
Significance was set at p ≤ 0.05.
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FIGURE 4 | The effects of 5FU on infiltrating skeletal muscle monocytes and macrophages. (A) CD11b+ monocytes were gated for their activation status using
Ly6C. Cells were considered either resident (Ly6cLow) or activated/infiltrating (Ly6cHigh). (B) Ly6cHigh monocytes were quantified and shown in the bar graph as
relative % of CD45+CD11b+ cells. (C) F4/80+ macrophages were gated analyzed for their polarization status using CD11c and CD206. (D) CD11c-CD206- cells
were considered M0-like macrophages, CD11c+CD206- cells were considered M1-like macrophages, CD11c-CD206+ cells were considered M2-like macrophages,
and CD11c+CD206+ cells were considered M1-M2-like transitional macrophages and graphed as the relative % of F480+ macrophages. Significance was set at
p < 0.05.*Significantly different from control (t-test).
RESULTS
Animal Characteristics
Body weights were monitored daily during the treatment period
and shown as a relative change (%) from Day 0. 5FU treated
mice exhibited body weight loss between day 0 and Day 5
(effect of time; p < 0.0001) and had reduced % body weight
between days 2 and 5 (2–8%) compared to controls (p < 0.0001)
(Figure 1A). 5FU reduced the overall average daily food intake
(g/day) by 20.5% (p = 0.006) compared to controls (Figure 1B).
Despite the reductions in body weight and food intake, there
were no observed differences between 5FU and controls in several
Frontiers in Physiology | www.frontiersin.org 7 December 2020 | Volume 11 | Article 593468
fphys-11-593468 December 1, 2020 Time: 20:29 # 8
VanderVeen et al. Chemotherapy and Skeletal Muscle Immune Cells



















Control Mean 1161 5824 685 475 1806 4018 852 385 646 625
SEM (398) (701) (230) (168) (337) (387) (222) (131) (150) (132)
5FU Mean 313* 3576* 119* 193 842* 2733* 250* 140* 423 269*
SEM (87) (389) (28) (59) (144) (276) (86) (25) (100) (48)
p-value 0.060 0.016 0.031 0.141 0.022 0.019 0.030 0.015 0.248 0.044
Values are means ± SEM. Absolute number of Ly6cHigh cells from the CD45+CD11b+ single cells. Absolute number of Ly6cLow cells from the CD45+CD11b+ single
cells. Absolute number of F4/80-Ly6cHigh cells from the CD45+CD11b+ single cells. Absolute number of F4/80+Ly6cHigh cells from the CD45+CD11b+ single cells.
Absolute number of F4/80+Ly6cLow cells from the CD45+CD11b+ single cells. Absolute number of F4/80-Ly6cLow cells from the CD45+CD11b+ single cells. Absolute
number of CD206-CD11c+ cells from the CD45+CD11b+F4/80+ single cells. Absolute number of CD206+CD11c+ cells from the CD45+CD11b+F4/80+ single cells.
Absolute number of CD206+CD11c- cells from the CD45+CD11b+F4/80+ single cells. Absolute number of CD206-CD11c- cells from the CD45+CD11b+F4/80+
single cells. Significance was set at p < 0.05. *Significantly different from Control using a student’s t-test.
hindlimb muscle weights, soleus (p = 0.35), plantaris (p = 0.96),
gastrocnemius (p = 0.57), extensor digitorum longus (p = 0.99),
tibialis anterior (p = 0.50), and quadriceps (p = 0.82) (Figure 1C).
Spleen weight was decreased 22.6% (p < 0.0001) with 5FU
(Figure 1D) which is further supported by a 46.4% (p = 0.001)
decrease in circulating leukocytes (Figure 1E). More specifically,
circulating lymphocytes and neutrophils were reduced with 5FU
by 33.3% (p = 0.006) and 83.5% (p = 0.002), respectively, with
no significant change in circulating monocytes (26.5% reduction,
p = 0.43) (Figure 1E). 5FU reduced circulating red blood cells
(RBC) by 16.2% (p = 0.002) with 20.8% (p = 0.0003) and 18.8%
(p = 0.0002) reductions in hemoglobin (HGB) and hematocrit
(HCT), respectively (Figure 1F). Additionally, 5FU decreased
platelets (PLT) by 62.6% (p < 0.0001; Figure 1F).
The Effect of 5FU on Skeletal Muscle
Monocytes
Cells isolated from the quadriceps underwent the following
gating procedures, which was previously described (Reidy et al.,
2019). Cells were first gated for “non-debris” by plotting SSC-
A × FSC-A (Figure 2A). Cells were then gated for single cells
by plotting SSC-W × SSC-H (Figure 2B) and then FSC-W
× FSC-H (Figure 2C). Immune cells were then gated from
“non-debris,” “SSC singlets,” and “FSC singlets” by plotting SSC-
A by CD45. CD45+ cells were considered all immune cells
and were quantified as a % of singlets (Figure 2D) and total
number of immune cells (Table 1). 5FU treatment resulted
in a 35.5% decrease (p = 0.003) in the relative quantity of
CD45+ immune cells (Figure 2E), and a 46.9% decrease in
total CD45+ immune cells (Table 1). CD45+ immune cells
were further gated with CD11b and CD45+CD11b+ cells were
classified as monocytes and were quantified as a % of CD45+
cells (Figure 2F) and total number of monocytes (Table 1).
The relative abundance of monocytes within CD45+ cells was
not significantly different (1.4%, p = 0.57) with 5FU treatment
(Figure 2G); however, total monocytes were reduced by 47.0%
with 5FU (Table 1). CD45+CD11b+ cells were further gated
with F4/80 and CD45+CD11b+F4/80+ cells were classified as
macrophages and were quantified as a % of CD45+CD11b
cells (Figure 2H) and total number of macrophages (Table 1).
5FU decreased the relative abundance of macrophages by 19.2%
within CD45+CD11b+ monocytes; however, this did not reach
statistical significance (p = 0.07; Figure 2I). 5FU reduced
total macrophage count by 56.8% (Table 1). Last, there was a
strong correlation between circulating leukocytes and skeletal
muscle CD45+ immune cells (R = 0.75; p = 0.003), CD11b+
monocytes (R = 0.69; p = 0.002), F4/80+macrophages (R = 0.67;
p = 0.002), and Ly6cHigh infiltrating monocytes (R = 0.67;
p = 0.008) in all mice.
Skeletal Muscle Inflammatory Gene
Expression
RNA was extracted from the gastrocnemius which shares a
similar myofibrillar myosin heavy chain isoform expression as
the quadriceps and is similarly a prime mover. There was no
difference in expression of total macrophage markers CD68 or
Emr1 (F4/80) with 5FU treatment (Figure 3A). Additionally,
there was no difference in M1-like macrophage gene Itgax
(CD11c) or M2-like macrophage gene Mrc1 (CD206) with 5FU
(Figure 3A). 5FU reduced pro-inflammatory cytokines, IL-1β
and IFNγ, 95% (p = 0.009) and 75% (p = 0.01), respectively,
while IL-6, TNFα, and MCP-1 were not changed (Figure 3B).
There were no differences in anti-inflammatory cytokines IL-10
and TGFβ with 5FU (Figure 3C).
The Effect of 5FU on Resident and
Infiltrating Skeletal Muscle Monocytes
and Macrophages
Given the decrease in pro-inflammatory cytokines IL-1β and
IFNγ, we sought to understand the phenotype of skeletal
muscle monocytes. Similar to Figure 2, cell singlets were
gated for CD45+CD11b+ followed by Ly6C to understand the
effects of 5FU on infiltrating monocytes. Ly6cHigh cells were
classified as infiltrating monocytes and were quantified as a % of
CD45+CD11b+ cells (Figure 4A) and total number of activated
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FIGURE 5 | The effects of 5FU on bone marrow immune cells. (A) Cells were gated for non-debris (SSC-A × FSC-A), (B) FSC singlets (FSC-W × FSC-H), (C) and
SSC singlets (SSC-W × SSC-H; A-right). (D) Non-debris singlet cells were then gated for total immune cells with CD45+. (E) CD45+ cells were quantified and
shown in the bar graph as the relative % of non-debris singlets. (F) CD45+ cells were gated for monocytes with CD11b+. (G) CD45+CD11b+ cells were quantified
and shown in the bar graph as the relative % of CD45+ cells. (H) CD11b+ monocytes were gated for their activation status using Ly6C. Cells were considered either
resident (Ly6cLow) or activated/infiltrating (Ly6cHigh). (I) Ly6cHigh monocytes were quantified and shown in the bar graph as relative % of CD45+CD11b+ cells.
Significance was set at p < 0.05. *Significantly different from Control using a student’s t-test.
monocytes (Table 2). 5FU decreased the relative abundance
of Ly6cHigh infiltrating monocytes by 49.9% (p = 0.02) within
CD45+CD11b+ monocytes (Figure 4B). Also, total Ly6cHigh
infiltrating monocytes were reduced by 73.0% with 5FU, but
this did not achieve statistical significance (p = 0.06; Table 2).
Total Ly6cLow, resident monocytes, were reduced by 38.6% with
5FU (Table 2). Given that the total number of macrophages
were reduced with 5FU (Table 1), we examined if there were
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TABLE 3 | Bone marrow immune cell population.
Total Non-debris FSC Singlet SSC Singlet CD45+ CD45+ CD11b+ CD45+ CD11b+ Ly6cHigh
Control Mean 500000 483227 465831 464058 304878 233494 160170
SEM 0 (1160) (2145) (2295) (50575) (44979) (40441)
5FU Mean 500000 409499* 401998* 400736* 246100 91678* 74938*
SEM 0 (8611) (8845) (8948) (26514) (19190) (16942)
p-value 0.00001 0.00003 0.00003 0.096 0.001 0.010
Values are means ± SEM. Total number of cells counted. Absolute number of non-debris cells from the total number of cells. Absolute number of forward scatter (FSC)
single cells from the non-debris cells. Absolute number of side scatter (SSC) single cells from the FSC single cells. Absolute number of CD45+ cells from the SSC single
cells. Absolute number of CD45+CD11b+ cells from SSC single cells. Absolute number of CD45+CD11b+Ly6cHigh cells from SSC single cells. Significance was set at
p < 0.05. *Significantly different from Control using a student’s t-test.
FIGURE 6 | The effects of 5FU on bone marrow cell cycle. (A) Cells were fixed and stained with Ki67 and propidium iodide (PI). (B) Cells in the G1/G0, S, and G2/M
phases were quantified and shown in the bar graph as the relative % of total cells. Significance was set at p < 0.05.*Significantly different from control (t-test).
changes in macrophage phenotype by measuring CD11c (M1-
like) and CD206 (M2-like) from parent CD45+CD11b+F4/80+
macrophages (Figure 4C). There were no observed changes
in the relative abundance of M1-like (p = 0.20), M2-like
(p = 0.12), M1-M2 transitional (p = 0.42), or M0 (p = 0.24)
macrophages with 5FU treatment (Figure 4D); however, 5FU
decreased total number of M1-like (CD11c+CD206-) by 70.7%,
M1-M2 transition (CD11c+CD206+) by 63.6%, and M0
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(CD11c-CD206-) macrophages by 57.0% (Table 2). The total
number of M2-like macrophages (CD11c-CD206+) cells were
not significantly different between groups (Table 2).
The Effects of 5FU on the Bone Marrow
In order to further understand the effects of 5FU on circulating
and infiltrating monocytes, we examined 5FU’s impact on
bone marrow cells (Figure 5). Bone marrow isolates were
obtained from both femurs of 5 mice/group. Cell gating of
bone marrow cells was performed as described for data in
Figures 2, 5A–D. 5FU decreased the relative abundance of
CD45+ immune cells by 12.9% (p = 0.03; Figure 5E) and total
CD45+ immune cells by 19.3% (Table 3), but the reduction in
total CD45+ immune cells did not reach statistical significance
(p = 0.096). CD45+ cells were further gated with CD11b and
CD45+CD11b+ cells were considered monocytes (Figure 5F)
and were quantified as a % of CD45+ cells (Figure 5G) and
total number of monocytes (Table 3). 5FU treatment reduced
the relative abundance of bone marrow monocytes by 50.3%
(p = 0.0002) within total CD45+ immune cells (Figure 5G)
and reduced total monocytes by 60.7%. CD45+CD11b+ cells
were further gated with Ly6C and CD45+CD11b+Ly6CHigh
cells were considered activated monocytes (Figure 5H) and were
quantified as a % of CD45+CD11b+ cells (Figure 5G) and total
number of activated monocytes (Table 3). 5FU treatment had
no apparent effect on the relative abundance of bone marrow
activated monocytes within total CD45+CD11b+ monocytes
(Figure 5I); however, the total number of activated monocytes
was reduced by 53.2% (Table 3). Additionally, 5FU induced cell
cycle arrest in the bone marrow (Figure 6). 5FU increased the
relative abundance of cells in the G1/G0 cell cycle phase by 12.0%
(p = 0.009) and decreased S and G2/M cell cycle phases by 82.4%
(p < 0.0001) and 69.1% (p < 0.0001), respectively (Figure 6B).
DISCUSSION
5 fluorouracil has been the first-choice chemotherapy drug
for several cancer types; however, its efficacy is diminished
by patient acquired resistance and pervasive side effects
contributing to reduced life quality and poor treatment
outcomes (van Kuilenburg and Maring, 2013; Giuliani and
Bonetti, 2016; Lee et al., 2016; McQuade et al., 2017).
Given 5FU’s deleterious effects on circulating leukocytes, the
purpose of our study was to investigate the acute effects of
5FU on resident and infiltrating skeletal muscle monocytes
and inflammatory mediators. Our results extend previous
studies to identify that 1 cycle of a clinically translatable
dose of 5FU significantly reduced CD45+ immune cells and
infiltrating/activated CD11b+Ly6CHigh monocytes in skeletal
muscle that was associated with a decrease in select skeletal
muscle inflammatory mediators. Additionally, the reduction in
skeletal muscle was accompanied by a reduction in bone marrow
monocytes and an increase in cell cycle arrest. These results
identify novel off-target effects of 5FU on skeletal muscle and
the skeletal muscle microenvironment independent of muscle
mass regulation.
Our understanding of chemotherapy-induced body weight
and function loss, termed cachexia, has improved over the last
decade (Gilliam et al., 2009; Barreto et al., 2016b; Morton et al.,
2019). Our investigation of the acute (1 cycle) effects of 5FU
demonstrated that 5FU induced clinically relevant body weight
loss (>5%) (Evans et al., 2008), which was accompanied with
signs of anorexia, but not skeletal muscle mass loss. Others
have demonstrated that 5 weeks of 5FU combination therapy,
Folfiri (leucovorin, 5FU, Irinotecan), decreased body weight and
lean mass over time, with corresponding reductions in several
hindlimb weights (Barreto et al., 2016b). Interestingly, mice
given 5 weeks of Folfox (leucovorin, 5FU, oxaliplatin) rather
than Folfiri maintained body weight and lean mass, and only
showed reduced quadriceps weight. Additionally, similar to the
doxorubicin effects on skeletal muscle (Gilliam et al., 2009;
Tarpey et al., 2019), only Folfiri reduced skeletal muscle specific
force (strength per muscle unit area) – which may occur through
several mechanisms including fibrosis (Barreto et al., 2016b).
Together this suggests that significant muscle mass loss only
occurs after sustained 5FU treatment (Barreto et al., 2016b,
2017), given that 1 week of 5FU was unable to reduce hindlimb
muscle weight. We then hypothesize that it is likely that anorexia
and dehydration contribute to the observed body weight loss as
these are commonly reported with 5FU (Liaw et al., 1999; Yi
et al., 2016). Additionally, the potential for body weight loss and
anorexia alone to contribute to the observed immune disruptions
cannot be ruled out. Unfortunately, however, a weight loss only
group was not included to test this hypothesis therefore limiting
our interpretations. Nonetheless, our results provide evidence
to suggest that 5FU-induced anemia and leukopenia are likely
to contribute to the observed functional pathologies that occur
with 5FU treatment.
The role of immune cells, particularly macrophages, in
skeletal muscle regeneration, repair, and remodeling has been
well characterized (Tidball, 2017); however, chemotherapy’s
effects on these processes is not well known. Following
skeletal muscle insult (e.g., damage, ischemia, exercise), there
is an initial influx of neutrophils which in turn recruit naïve
monocytes primarily through the release of MCP-1 (Deshmane
et al., 2009; Tidball, 2017). We have previously shown that
5FU induced circulating MCP-1 after 14 days of treatment,
which was associated with reduced voluntary physical activity
(Mahoney et al., 2013). The monocytes recruited by MCP-1
are primarily recruited as CD11b+Ly6CHigh monocytes which
can either remain as such or differentiate and polarize to a
pro-inflammatory M1-like F4/80+CD11c+CD206- macrophage
(Tidball, 2005; Guilliams et al., 2014; Yang et al., 2014). Following
an acute 5FU regime (1 week) we document a reduction in
total and relative Ly6CHigh monocytes as well as total M1-
like F4/80+CD11c+CD206- macrophages in skeletal muscle
despite no changes in skeletal muscle pro-inflammatory MCP-
1, IL-6, and TNFα levels. However, we did observe decreased
expression of pro-inflammatory genes associated with M1-like
macrophages, IL-1β and IFNγ, but on the other hand did not
observe corresponding changes to total M1-like macrophage
cell surface marker, Itgax, more commonly known as CD11c
(Jablonski et al., 2015). These discrepancies between the flow
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cytometry and gene transcription require additional work and
thus, interpretations should be taken with caution; however,
flow cytometry remains the gold standard for the assessment of
immune cells, and it appears evident that 5FU has deleterious
effects on the pro-inflammatory monocytes and macrophages.
A loss of pro-inflammatory or phagocytic M1-like macrophages
could negatively impact skeletal muscle remodeling and repair
(Tidball, 2005). Chemotherapeutic doxorubicin has been shown
to blunt the pro-inflammatory response following exercise which
mitigated the muscle’s response to exercise (Huang et al.,
2017). Furthermore, while repeated muscular contractions were
able to improve muscle mass in cancer patients undergoing
treatment, patients did not obtain the functional and metabolic
improvements that have been previously seen with exercise
(Guigni et al., 2019; Toth et al., 2020). While chemotherapeutics
5FU and doxorubicin mechanisms of action differ, we can
still glean potential mechanisms and clinical manifestations.
To the best of our knowledge, we are the first to document
that 5FU disrupts skeletal muscle’s pro-inflammatory immune
cell environment. It is also important to note that these cell
surface markers and the M1/M2 dichotomous classification of
macrophages does not properly reflect the true diversity and
nature of resident/infiltrating macrophages and should again be
interpreted cautiously (Davies et al., 2013; Guilliams et al., 2014;
Martinez and Gordon, 2014; Tidball, 2017).
Tissue resident macrophages are classically CD206+ anti-
inflammatory, pro-fibrotic surveying macrophages (Gordon
and Taylor, 2005; Murray and Wynn, 2011; Cote et al.,
2013; Guilliams et al., 2014); however, macrophages are
plastic and as skeletal muscle repair progresses the infiltrated
M1-like F4/80+CD11c+ macrophages can reduce the gene
expression and release of pro-inflammatory mediators and
become more phenotypically M2-like to promote extracellular
matrix remodeling and angiogenesis (Schiaffino et al., 2017; De
Santa et al., 2018; Shapouri-Moghaddam et al., 2018). Others
have proposed that resident macrophages are predominantly
M0 (CD11c-CD206-) which are self-maintained, proliferate,
and polarize to an M1-like phenotype upon activation during
the initial stages of injury repair (Cote et al., 2013; Tidball,
2017). Regardless, our results demonstrate that the relative
phenotype of skeletal muscle macrophages is not changed
by 5FU treatment; however, the total number of M1-like
(CD11c+CD206-), M0-like (CD11c-CD206-), and M1-M2-like
transitional macrophages were reduced with 5FU while M2-
like macrophages appear spared from 5FU’s cytotoxicity – at
least following 1 week of 5FU. Additionally, anti-inflammatory
IL-10, pro-fibrotic TGFβ, and M2-like macrophage cell surface
marker Mrc1, commonly known as CD206, gene transcription
were not changed by 5FU treatment. The potential for 5FU to
target M1-like macrophages rather than M2-like, points to a pro-
fibrotic skeletal muscle microenvironment. 5FU combination
therapy Folfiri was shown to reduce skeletal muscle specific force
(force per unit area); however, neither fibrosis nor an increase in
fibrotic genes (TGF-β associated ligands) were apparent (Barreto
et al., 2016b). Therefore, it is likely that these pro-fibrotic
M2-like cells remain at a physiological abundance during 5FU
treatment and may not be contributing to a skeletal muscle
pathology directly. Interestingly, TAMs phenotypically reflect
M2-like macrophages promoting immunosuppression, fibrosis,
and angiogenesis, within the tumor microenvironment and have
been associated with 5FU acquired resistance (Zhang et al., 2016).
The potential for M2-like macrophages to be protected against
5FU requires significant attention in the cancer domain.
Chemotherapy has been shown to mitigate the inflammatory
response with exercise (Huang et al., 2017; Smuder, 2019), induce
leukopenia/cytopenia (Shitara et al., 2011), and disrupt cardiac
macrophage infiltration (Johnson and Singla, 2018). To the best
of our knowledge, this is the first study to demonstrate that
chemotherapeutic 5FU has deleterious effects on immune cell
abundance in otherwise healthy uninjured skeletal muscle. The
absolute reduction in macrophage number rather than relative
changes in abundance remains relevant given the physiological
importance of the overall immune response in repair and
remodeling (Summan et al., 2006; Segawa et al., 2008; Cote et al.,
2013; Xiao et al., 2016; Zhao et al., 2016; Inaba et al., 2018).
The mean age of cancer patients is ∼65 years and overlapping
sarcopenic and cachectic factors along with chemotherapy may
contribute to disrupted skeletal muscle immune regulation
(Dunne et al., 2019). Disrupted skeletal muscle repair associated
with changes in macrophages has been reported with aging
(Reidy et al., 2019), cancer (Inaba et al., 2018), and chemotherapy
(Huang et al., 2017). The effects of aging on skeletal muscle
macrophages has demonstrated that reloading aged skeletal
muscle had a blunted hypertrophy response associated with
a lower number of M1-like macrophages at baseline and
blunted M1-like macrophage infiltration (early) and M2-like
macrophage transition (late) (Reidy et al., 2019). Surprisingly,
while inflammation is a hallmark of cancer cachexia associated
with muscle weakness and fatigue (VanderVeen et al., 2017,
2018), total macrophage number was reduced in damaged muscle
of C26 tumor-bearing mice compared to a non-cachectic tumor-
bearing control (Inaba et al., 2018). Additionally, macrophages
were shown to regulate skeletal muscle signal transducer and
activator of transcription 3 (STAT3) – downstream target of IL-6
and key regulator of skeletal muscle mitochondrial homeostasis
and proteostasis (Carson and Kristen, 2010; Bonetto et al.,
2011, 2012; VanderVeen et al., 2017, 2019) – during pancreatic
cancer cachexia (Shukla et al., 2020). Further work is needed
to understand these potentially overlapping mechanisms with
cancer and chemotherapy on skeletal muscle immune cells.
Chemotherapy’s effects on systemic inflammatory mediators
(Lee et al., 2014; Ribeiro et al., 2016; Derman et al.,
2017; Sougiannis et al., 2019) and intrinsic skeletal muscle
inflammatory signaling (Kvinnsland, 1999; Yamanaka et al., 2007;
Shitara et al., 2009; Baechler et al., 2010; Han et al., 2012; Abraham
et al., 2015) are continuing to be unearthed; however, our study is
the first to identify that 5FU-induced leukopenia extends beyond
circulation to impact the skeletal muscle microenvironment.
Our results indicate that 5FU’s toxic effects on skeletal muscle
leukocytes are not necessarily specific to monocytes shown
by no change in both circulating monocyte count or relative
abundance of skeletal muscle CD11b+ monocytes within the
CD45+ population. This is not to say that monocytes are
spared from 5FU as the total number of skeletal muscle
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monocytes are reduced. Bone marrow CD11b+ monocytes and
the relative abundance of infiltrating Ly6CHigh monocytes in
skeletal muscle were reduced with 5FU which is supported
by the established deleterious effects of 5FU on circulating
leukocytes and the hematopoietic system (Yamanaka et al.,
2007; Lee et al., 2016; Sougiannis et al., 2019). In conjunction
with previous studies, our results support that 5FU’s toxicity
is predominantly associated with pro-inflammatory mediators
extending beyond the hematopoietic system to impact the skeletal
muscle microenvironment. Another potential mechanism for
the observed impact of 5FU on skeletal muscle immune cells
is the potential for reduced proliferation of pro-inflammatory
macrophages within the muscle microenvironment. Given that
circulating and skeletal muscle monocytes/macrophages are
not proportionally reduced it is possible that 5FU increased
maturation of monocytes within the skeletal muscle as well as
increased proliferation of M2-like macrophages.
CONCLUSION
Understanding chemotherapy’s off-target effects will allow for
improvements to treatment efficacy aimed at increasing cancer
patient survival and quality of life. Our novel finding that
chemotherapeutic 5FU depletes skeletal muscle immune cells and
infiltrating monocytes provides insight into the skeletal muscle
microenvironment that may contribute to weakness, fatigue,
and treatment intolerance (Williams et al., 2018). We provide
evidence to suggest that 5FU reduced circulating and skeletal
muscle leukocytes through disrupting the hematopoietic system
by inducing cell cycle arrest in the bone marrow. While our
results are limited to 5FU’s acute toxicities, future studies are
needed to understand the long-term implications of this loss
of immune cells and if chronic 5FU exposure exacerbates this
immune dysregulation. Furthermore, additional work is needed
to determine if mitigating the loss of immune cells can improve
skeletal muscle function following repeated cycles of 5FU.
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